Patents by Inventor John Mark Sutton
John Mark Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11942809Abstract: A charger system comprising a charging station including a plurality of nests for chargers is described. Each of the plurality of nests is designed to partially eject the charger when instructed to do so, and further comprises a nest lock to lock in the charger into the nest when not ejecting. The charger system interacting with a user account, enabling a user to request the charger, wherein the charger is ejected from the nest for a valid request.Type: GrantFiled: August 12, 2022Date of Patent: March 26, 2024Assignee: Juize, Inc.Inventors: Mukhabbatov Nasim Khokimovich, Alex Freed, John Mark Sutton, Øivind Alexander Slaatto
-
Patent number: 11746116Abstract: The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C6-10 aryl, C7-13 aralkyl, C5-10 heteroaryl, C6-13 heteroaralkyl, C5-10 heterocyclyl, C6-13 heterocyclalkyl, C3-10 carbocyclyl, C4-13 carbocyclalkyl, —C(?NR?)—NR?R? or —CH2—CH?CH2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infections, such as drug-resistant bacterial infections.Type: GrantFiled: May 30, 2018Date of Patent: September 5, 2023Assignees: King's College London, Secretary of State for Health and Social CareInventors: Khondaker Mirazur Rahman, Shirin Jamshidi, Mark Benjamin Laws, Kazi Nahar, John Mark Sutton, Charlotte Hind
-
Publication number: 20230140713Abstract: Methods are presented which use impedance flow cytometry for rapid susceptibility testing of antimicrobial agents including phage, antimicrobial peptides and rapid analysis of antimicrobial mediated serum bactericidal assays.Type: ApplicationFiled: March 19, 2021Publication date: May 4, 2023Applicants: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE, THE UNIVERSITY OF SOUTHAMPTONInventors: John Mark Sutton, Charlotte Hind, Hywel Morgan, Daniel Spencer
-
Publication number: 20230047825Abstract: The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.Type: ApplicationFiled: December 1, 2020Publication date: February 16, 2023Inventors: John Mark SUTTON, Andrew James MASON, Richard Thomas AMISON
-
Patent number: 11418044Abstract: A charger system comprising a charging station including a plurality of nests for chargers is described. Each of the plurality of nests is designed to partially eject the charger when instructed to do so, and further comprises a nest lock to lock in the charger into the nest when not ejecting. The charger system interacting with a user account, enabling a user to request the charger, wherein the charger is ejected from the nest for a valid request.Type: GrantFiled: January 14, 2020Date of Patent: August 16, 2022Assignee: Juize, Inc.Inventors: Mukhabbatov Nasim Khokimovich, Alex Freed, John Mark Sutton, Øivind Alexander Slaatto
-
Publication number: 20210261570Abstract: The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C6-10 aryl, C7-13 aralkyl, C5-10 heteroaryl, C6-13 heteroaralkyl, C5-10 heterocyclyl, C6-13 heterocyclalkyl, C3-10 carbocyclyl, C4-13 carbocyclalkyl, —C(?NR?)—NR?R? or —CH2—CH?CH2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infractions, such as drug-resistant bacterial infections.Type: ApplicationFiled: May 30, 2018Publication date: August 26, 2021Inventors: Khondaker Mirazur RAHMAN, Shirin JAMSHIDI, Mark Benjamin LAWS, Kazi NAHAR, John Mark SUTTON, Charlotte HIND
-
Patent number: 10640507Abstract: The invention relates to pyrrolobenzodiazepines compounds (PBDs) and to pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular, to treat bacterial infections.Type: GrantFiled: December 9, 2016Date of Patent: May 5, 2020Assignees: King's College London, Secretary of State for Health and Social CareInventors: Khondaker Mirazur Rahman, John Mark Sutton, Pietro Picconi
-
Publication number: 20190352700Abstract: Carbapenem-resistant bacteria is detected and carbapenem-resistant bacteria infection is diagnosed. Primers and probes are used for particular carbapenemase genes, which enable the accurate detection of carbapenem-resistant bacteria.Type: ApplicationFiled: April 27, 2017Publication date: November 21, 2019Inventors: John Mark SUTTON, Carrie TURNER, Collette ALLEN
-
Publication number: 20180354958Abstract: The invention relates to pyrrolobenzodiazepines compounds (PBDs) and to pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular, to treat bacterial infections.Type: ApplicationFiled: December 9, 2016Publication date: December 13, 2018Inventors: Khondaker Mirazur RAHMAN, John Mark SUTTON, Pietro PICCONI
-
Publication number: 20140315215Abstract: There is provided a single-chain fusion protein comprising: (i) a thermostable kinase and (ii) a single-domain antibody or single-domain antibody fragment. There is also provided a method of preparing a single-domain antibody or single-domain antibody fragment, the method comprising: (i) expressing the single-domain antibody or antibody fragment as a single-chain fusion protein with a thermostable kinase, in a host cell such as E. coli; and (ii) purifying the fusion protein from the cytoplasm of the host cell.Type: ApplicationFiled: September 14, 2012Publication date: October 23, 2014Applicant: The Secretary of State for HealthInventors: John Mark Sutton, Philip James Alister Skipper
-
Publication number: 20120128700Abstract: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and is not a fragment or derivative of a HN domain of a clostridial toxin.Type: ApplicationFiled: February 1, 2012Publication date: May 24, 2012Applicant: SYNTAXIN LIMITEDInventors: Clifford Charles SHONE, John Mark SUTTON, Nigel SILMAN
-
Patent number: 8110391Abstract: A transmissible spongiform encephalopathy (TSE) agent is inactivated by exposing the TSE agent to a thermostable proteolytic enzyme at elevated temperature and at acid or alkaline pH. Following this step, or separately, presence of TSE infectivity is detected by detection of dimers of prion protein.Type: GrantFiled: October 11, 2007Date of Patent: February 7, 2012Assignee: Health Protection AgencyInventors: Neil David Hammond Raven, John Mark Sutton
-
Publication number: 20090269361Abstract: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and is not a fragment or derivative of a HN domain of a clostridial toxin.Type: ApplicationFiled: May 17, 2007Publication date: October 29, 2009Inventors: Clifford Charles Shone, John Mark Sutton, Nigel Silman
-
Patent number: 7470661Abstract: A composition for delivery of superoxide dismutase to neuronal cells comprise a superoxide dismutase linked by a linker to a neuronal cell targeting component, which component comprises a first domain that binds to a neuronal cell and a second domain that translocates the superoxide dimutase into the neuronal cell. After translocation, the linker is cleaved to release superoxide dimutase from the neuronal cell targeting domain. Also described is use of the composition for treatment of oxidative damage to neuronal cells and further targeting of the composition using human mitochondrial leader sequences. A hybrid polypeptide is described that contains a bacterial superoxide dismutase plus a sequence that targets a human mitochondira.Type: GrantFiled: February 22, 2005Date of Patent: December 30, 2008Assignee: Syntaxin LimitedInventors: Clifford Charles Shone, John Mark Sutton, Bassam Hallis, Nigel Silman
-
Publication number: 20080178306Abstract: A transmissible spongiform encephalopathy (TSE) agent is inactivated by exposing the TSE agent to a thermostable proteolytic enzyme at elevated temperature and at acid or alkaline pH. Following this step, or separately, presence of TSE infectivity is detected by detection of dimers of prion protein.Type: ApplicationFiled: October 11, 2007Publication date: July 24, 2008Inventors: Neil David Hammond Raven, John Mark Sutton
-
Patent number: 7368532Abstract: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and is not a fragment or derivative of a HN domain of a clostridial toxin.Type: GrantFiled: December 4, 2000Date of Patent: May 6, 2008Assignee: Syntaxin LimitedInventors: Clifford Charles Shone, John Mark Sutton, Nigel Silman
-
Publication number: 20040208889Abstract: A polypeptide conjugate contains a bacterial injectable effector protein, secreted by a modified pilus or “needle-like” structure comprising a type m or type TV secretion apparatus, and a carrier that targets the conjugate to a target cell. The effector protein is used for a variety of purposes including treatment of neurodegenerative disease, intracellular infection and diseases associated with defects of secretion.Type: ApplicationFiled: May 26, 2004Publication date: October 21, 2004Inventors: John Mark Sutton, Clifford Charles Shone
-
Publication number: 20040091474Abstract: A transmissible spongiform encephalopathy (TSE) agent is inactivated by exposing the TSE agent to a thermostable proteolytic enzyme at elevated temperature and at acid or alkaline pH. Following this step, or separately, presence of TSE infectivity is detected by detection of dimers of prion protein.Type: ApplicationFiled: July 8, 2003Publication date: May 13, 2004Applicant: Health Protection AgencyInventors: Neil David Hammond Raven, John Mark Sutton
-
Publication number: 20030147895Abstract: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and is not a fragment or derivative of a HN domain of a clostridial toxin.Type: ApplicationFiled: June 25, 2002Publication date: August 7, 2003Inventors: Clifford Charles Shone, John Mark Sutton, Nigel Silman